Literature DB >> 23558664

The relationship between passive stiffness and muscle power output: influence of muscle cross-sectional area normalization.

Ty B Palmer1, Nathaniel D M Jenkins, Brennan J Thompson, Douglas B Smith, Joel T Cramer.   

Abstract

INTRODUCTION: We examined the relationship between passive stiffness of posterior hip and thigh muscles and muscle power output before and after normalization of passive stiffness to muscle cross-sectional area (CSA).
METHODS: Pearson correlation coefficients (r) were used to assess the relationships between the normalized and non-normalized slopes of the initial (phase 1) and final (phase 2) portions of the angle-torque curve and peak power output (Pmax).
RESULTS: A significant positive relationship was observed between the non-normalized slope of phase 1 and Pmax (r = 0.723; P ≤ 0.001); however, no correlations were observed between the normalized slope of phase 1 and Pmax (r = 0.244; P = 0.299) nor between Pmax and the normalized and non-normalized slopes of phase 2 (r = -0.159-0.418; P = 0.067-0.504).
CONCLUSIONS: The findings suggest that muscle size, rather than stiffness, accounted for a significant portion of the variance in muscle power output.
Copyright © 2013 Wiley Periodicals, Inc.

Keywords:  musculotendinous unit; normalization; passive stiffness; power; vertical jump performance

Mesh:

Year:  2013        PMID: 23558664     DOI: 10.1002/mus.23861

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  2 in total

1.  Dorsiflexion, plantar-flexion, and neutral ankle positions during passive resistance assessments of the posterior hip and thigh muscles.

Authors:  Ty B Palmer; Kazuma Akehi; Ryan M Thiele; Douglas B Smith; Aric J Warren; Brennan J Thompson
Journal:  J Athl Train       Date:  2015-02-06       Impact factor: 2.860

2.  Does work-induced fatigue accumulate across three compressed 12 hour shifts in hospital nurses and aides?

Authors:  Brennan J Thompson
Journal:  PLoS One       Date:  2019-02-07       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.